» Articles » PMID: 31256696

Coronary Artery Disease Risk and Lipidomic Profiles Are Similar in Hyperlipidemias With Family History and Population-Ascertained Hyperlipidemias

Abstract

Background We asked whether, after excluding familial hypercholesterolemia, individuals with high low-density lipoprotein cholesterol ( LDL -C) or triacylglyceride levels and a family history of the same hyperlipidemia have greater coronary artery disease risk or different lipidomic profiles compared with population-based hyperlipidemias. Methods and Results We determined incident coronary artery disease risk for 755 members of 66 hyperlipidemic families (≥2 first-degree relatives with similar hyperlipidemia) and 19 644 Finnish FINRISK population study participants. We quantified 151 circulating lipid species from 550 members of 73 hyperlipidemic families and 897 FINRISK participants using mass spectrometric shotgun lipidomics. Familial hypercholesterolemia was excluded using functional LDL receptor testing and genotyping. Hyperlipidemias ( LDL -C or triacylglycerides >90th population percentile) associated with increased coronary artery disease risk in meta-analysis of the hyperlipidemic families and the population cohort (high LDL -C: hazard ratio, 1.74 [95% CI, 1.48-2.04]; high triacylglycerides: hazard ratio, 1.38 [95% CI, 1.09-1.74]). Risk estimates were similar in the family and population cohorts also after adjusting for lipid-lowering medication. In lipidomic profiling, high LDL -C associated with 108 lipid species, and high triacylglycerides associated with 131 lipid species in either cohort (at 5% false discovery rate; P-value range 0.038-2.3×10). Lipidomic profiles were highly similar for hyperlipidemic individuals in the families and the population ( LDL -C: r=0.80; triacylglycerides: r=0.96; no lipid species deviated between the cohorts). Conclusions Hyperlipidemias with family history conferred similar coronary artery disease risk as population-based hyperlipidemias. We identified distinct lipidomic profiles associated with high LDL -C and triacylglycerides. Lipidomic profiles were similar between hyperlipidemias with family history and population-ascertained hyperlipidemias, providing evidence of similar and overlapping underlying mechanisms.

Citing Articles

Traditional Therapeutics and Potential Epidrugs for CVD: Why Not Both?.

Gladwell L, Ahiarah C, Rasheed S, Rahman S, Choudhury M Life (Basel). 2024; 14(1).

PMID: 38255639 PMC: 10820772. DOI: 10.3390/life14010023.


Lipidomics-Paving the Road towards Better Insight and Precision Medicine in Rare Metabolic Diseases.

Zandl-Lang M, Plecko B, Kofeler H Int J Mol Sci. 2023; 24(2).

PMID: 36675224 PMC: 9866746. DOI: 10.3390/ijms24021709.


Treatment of Dyslipidemia through Targeted Therapy of Gut Microbiota.

Flaig B, Garza R, Singh B, Hamamah S, Covasa M Nutrients. 2023; 15(1).

PMID: 36615885 PMC: 9823358. DOI: 10.3390/nu15010228.


Multi-Omics Investigation into Acute Myocardial Infarction: An Integrative Method Revealing Interconnections amongst the Metabolome, Lipidome, Glycome, and Metallome.

Lim S, Lim F, Criado-Navarro I, Yeo X, Dayal H, Vemulapalli S Metabolites. 2022; 12(11).

PMID: 36355163 PMC: 9693522. DOI: 10.3390/metabo12111080.


Clinical lipidomics - A community-driven roadmap to translate research into clinical applications.

Vvedenskaya O, Holcapek M, Vogeser M, Ekroos K, Meikle P, Bendt A J Mass Spectrom Adv Clin Lab. 2022; 24:1-4.

PMID: 35199094 PMC: 8844780. DOI: 10.1016/j.jmsacl.2022.02.002.


References
1.
Berglund L, Brunzell J, Goldberg A, Goldberg I, Sacks F, Murad M . Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012; 97(9):2969-89. PMC: 3431581. DOI: 10.1210/jc.2011-3213. View

2.
Grundy S, Stone N, Bailey A, Beam C, Birtcher K, Blumenthal R . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; 139(25):e1082-e1143. PMC: 7403606. DOI: 10.1161/CIR.0000000000000625. View

3.
Matyash V, Liebisch G, Kurzchalia T, Shevchenko A, Schwudke D . Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J Lipid Res. 2008; 49(5):1137-46. PMC: 2311442. DOI: 10.1194/jlr.D700041-JLR200. View

4.
Genest Jr J, McNamara J, Ordovas J, Jenner J, Myers R, Silberman S . Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992; 85(6):2025-33. DOI: 10.1161/01.cir.85.6.2025. View

5.
Raatz S, Bibus D, Thomas W . Total fat intake modifies plasma fatty acid composition in humans. J Nutr. 2001; 131(2):231-4. DOI: 10.1093/jn/131.2.231. View